Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation.

Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, Ciceri F, Cornelissen J, Malladi R, Duarte RF, Giebel S, Greinix H, Holler E, Lawitschka A, Mielke S, Mohty M, Arat M, Nagler A, Passweg J, Schoemans H, Socié G, Solano C, Vrhovac R, Zeiser R, Kröger N, Basak GW.

Lancet Haematol. 2020 Feb;7(2):e157-e167. doi: 10.1016/S2352-3026(19)30256-X. Review.

PMID:
32004485
2.

The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience.

Loke J, Malladi R, Moss P, Craddock C.

Br J Haematol. 2020 Jan;188(1):129-146. doi: 10.1111/bjh.16355. Epub 2019 Dec 10. Review.

3.

Postremission Consolidation by Autologous Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia in First Complete Remission (CR) and Negative Implications for Subsequent Allogeneic HCT in Second CR: A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).

Passweg JR, Labopin M, Christopeit M, Cornelissen J, Pabst T, Socié G, Russel N, Yakoub-Agha I, Blaise D, Gedde-Dahl T, Labussière-Wallet H, Malladi R, Forcade E, Maury S, Polge E, Lanza F, Gorin NC, Mohty M, Nagler A.

Biol Blood Marrow Transplant. 2019 Nov 21. pii: S1083-8791(19)30788-8. doi: 10.1016/j.bbmt.2019.11.021. [Epub ahead of print]

PMID:
31759159
4.

Characteristics of graft-versus-host disease occurring after alemtuzumab-containing allogeneic stem cell transplants: incidence, organ involvement, risk factors and survival.

Finazzi MC, Boschini C, Craddock C, Rambaldi A, Ward J, Malladi RK.

Br J Haematol. 2020 Feb;188(4):550-559. doi: 10.1111/bjh.16200. Epub 2019 Nov 12.

PMID:
31713861
5.

Very early lineage-specific chimerism after reduced intensity stem cell transplantation is highly predictive of clinical outcome for patients with myeloid disease.

Kinsella FAM, Inman CF, Gudger A, Chan YT, Murray DJ, Zuo J, McIlroy G, Nagra S, Nunnick J, Holder K, Wall K, Griffiths M, Craddock C, Nikolousis E, Moss P, Malladi R.

Leuk Res. 2019 Aug;83:106173. doi: 10.1016/j.leukres.2019.106173. Epub 2019 Jun 18.

PMID:
31276965
6.

Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBI.

Nagler A, Labopin M, Dholaria B, Niittyvuopio R, Maertens J, Poiré X, Cornelissen J, Reményi P, Bourhis JH, Beguin Y, Malladi R, Kerre T, Schroyens W, Savani BN, Mohty M.

Blood Adv. 2019 Jul 9;3(13):1950-1960. doi: 10.1182/bloodadvances.2019000030.

7.

Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia.

Canaani J, Labopin M, Itälä-Remes M, Blaise D, Socié G, Forcade E, Maertens J, Wu D, Malladi R, Cornelissen JJ, Huynh A, Bourhis JH, Esteve J, Mohty M, Nagler A.

Leukemia. 2019 Aug;33(8):1944-1952. doi: 10.1038/s41375-019-0439-3. Epub 2019 Mar 7.

PMID:
30846862
8.

Mixed chimerism established by hematopoietic stem cell transplantation is maintained by host and donor T regulatory cells.

Kinsella FAM, Zuo J, Inman CF, Pearce H, Maggs L, Eldershaw SE, Chan YLT, Nunnick J, Nagra S, Griffiths M, Craddock C, Malladi R, Moss P.

Blood Adv. 2019 Mar 12;3(5):734-743. doi: 10.1182/bloodadvances.2018025502.

9.

Prolonged norovirus shedding and the use of a rapid norovirus polymerase chain reaction to assess terminal room cleaning in immunocompromised patients.

Smith C, Casey A, Round SL, Malladi R, Holden E, Garvey MI.

J Hosp Infect. 2019 Jul;102(3):354-355. doi: 10.1016/j.jhin.2019.02.006. Epub 2019 Feb 19. No abstract available.

PMID:
30790606
10.

Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia.

Craddock C, Slade D, De Santo C, Wheat R, Ferguson P, Hodgkinson A, Brock K, Cavenagh J, Ingram W, Dennis M, Malladi R, Siddique S, Mussai F, Yap C.

J Clin Oncol. 2019 Mar 1;37(7):580-588. doi: 10.1200/JCO.18.00889. Epub 2019 Jan 17.

PMID:
30653424
11.

Impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned-alemtuzumab allogeneic haematopoietic stem cell transplantation for patients with mature lymphoid malignancies.

Brierley CK, Jones FM, Hanlon K, Peniket AJ, Hatton C, Collins GP, Schuh A, Medd P, Clark A, Ward J, Chaganti S, Malladi R, Parker A, Craddock C, Danby R, Rocha V.

Br J Haematol. 2019 Feb;184(4):547-557. doi: 10.1111/bjh.15685. Epub 2018 Nov 22.

PMID:
30467838
12.

Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party.

Bazarbachi A, Boumendil A, Finel H, Mohty M, Castagna L, Blaise D, Peggs KS, Afanasyev B, Diez-Martin JL, Corradini P, Michonneau D, Robinson S, Gutiérrez García G, Bonifazi F, Yakoub-Agha I, Gülbas Z, Bloor A, Delage J, Esquirol A, Malladi R, Scheid C, El-Cheikh J, Ghesquières H, Montoto S, Dreger P, Sureda A.

Cancer. 2019 Jan 1;125(1):90-98. doi: 10.1002/cncr.31755. Epub 2018 Oct 23.

13.

The Impact of Advanced Patient Age on Mortality after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: A Retrospective Study by the European Society for Blood and Marrow Transplantation Lymphoma Working Party.

Kyriakou C, Boumendil A, Finel H, Nn Norbert Schmitz, Andersen NS, Blaise D, Chevallier P, Browne P, Malladi R, Niederwieser D, Pagliuca A, Kroschinsky F, Montoto S, Dreger P; EBMT Lymphoma Working Party.

Biol Blood Marrow Transplant. 2019 Jan;25(1):86-93. doi: 10.1016/j.bbmt.2018.08.025. Epub 2018 Sep 13.

14.

Unique features and clinical importance of acute alloreactive immune responses.

Inman CF, Eldershaw SA, Croudace JE, Davies NJ, Sharma-Oates A, Rai T, Pearce H, Sirovica M, Chan YLT, Verma K, Zuo J, Nagra S, Kinsella F, Nunnick J, Amel-Kashipaz R, Craddock C, Malladi R, Moss P.

JCI Insight. 2018 May 17;3(10). pii: 97219. doi: 10.1172/jci.insight.97219. eCollection 2018 May 17.

15.

Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party.

Bazarbachi A, Boumendil A, Finel H, Mohty M, Castagna L, Peggs KS, Blaise D, Afanasyev B, Diez-Martin JL, Sierra J, Bloor A, Martinez C, Robinson S, Malladi R, El-Cheikh J, Corradini P, Montoto S, Dreger P, Sureda A.

Br J Haematol. 2018 Apr;181(1):86-96. doi: 10.1111/bjh.15152. Epub 2018 Feb 22.

PMID:
29468647
16.

The number of CD56dim NK cells in the graft has a major impact on risk of disease relapse following allo-HSCT.

Maggs L, Kinsella F, Chan YLT, Eldershaw S, Murray D, Nunnick J, Bird J, Craddock C, Zuo J, Malladi R, Moss P.

Blood Adv. 2017 Aug 21;1(19):1589-1597. doi: 10.1182/bloodadvances.2017008631. eCollection 2017 Aug 22.

17.

High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party.

Akhtar S, Montoto S, Boumendil A, Finel H, Masszi T, Jindra P, Nemet D, Fuhrmann S, Beguin Y, Castagna L, Ferrara F, Capria S, Malladi R, Moraleda JM, Bloor A, Ghesquières H, Meissner J, Sureda A, Dreger P.

Am J Hematol. 2018 Jan;93(1):40-46. doi: 10.1002/ajh.24927. Epub 2017 Nov 9.

18.

NK cells produce high levels of IL-10 early after allogeneic stem cell transplantation and suppress development of acute GVHD.

Chan YLT, Zuo J, Inman C, Croft W, Begum J, Croudace J, Kinsella F, Maggs L, Nagra S, Nunnick J, Abbotts B, Craddock C, Malladi R, Moss P.

Eur J Immunol. 2018 Feb;48(2):316-329. doi: 10.1002/eji.201747134. Epub 2017 Oct 27.

19.

Provision of cellular blood components to CMV-seronegative patients undergoing allogeneic stem cell transplantation in the UK: survey of UK transplant centres.

Morton S, Peniket A, Malladi R, Murphy MF.

Transfus Med. 2017 Dec;27(6):444-450. doi: 10.1111/tme.12461. Epub 2017 Sep 15.

PMID:
28913908
20.

U.K. national audit of extracorporeal photopheresis in cutaneous T-cell lymphoma.

Sanyal S, Child F, Alfred A, Callaghan T, Alband N, Whittaker S, Cowan R, Parry E, Robinson S, Dunnill MGS, Wain M, Morris S, Malladi R, Tahir S, Howles A, Arumainathan A, Azurdia R, Grant-Casey J, Matin RN, Gilson D, Howell C, El-Gheriani K, Taylor P, Scarisbrick J.

Br J Dermatol. 2018 Feb;178(2):569-570. doi: 10.1111/bjd.15871. Epub 2018 Jan 12. No abstract available.

PMID:
28782100
21.

UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy.

Douglas KW, Gilleece M, Hayden P, Hunter H, Johnson PRE, Kallmeyer C, Malladi RK, Paneesha S, Pawson R, Quinn M, Raj K, Richardson D, Robinson S, Russell N, Snowden J, Sureda A, Tholouli E, Thomson K, Watts M, Wilson KM.

J Clin Apher. 2018 Feb;33(1):46-59. doi: 10.1002/jca.21563. Epub 2017 Jun 20. Review.

PMID:
28631842
22.

A disease-linked ULBP6 polymorphism inhibits NKG2D-mediated target cell killing by enhancing the stability of NKG2D ligand binding.

Zuo J, Willcox CR, Mohammed F, Davey M, Hunter S, Khan K, Antoun A, Katakia P, Croudace J, Inman C, Parry H, Briggs D, Malladi R, Willcox BE, Moss P.

Sci Signal. 2017 May 30;10(481). pii: eaai8904. doi: 10.1126/scisignal.aai8904.

PMID:
28559451
23.

Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party.

Bento L, Boumendil A, Finel H, Le Gouill S, Amorim S, Monjanel H, Bouabdallah R, Bay JO, Nicolas-Virelizier E, McQuaker G, Rossi G, Johnson R, Huynh A, Ceballos P, Rambaldi A, Bachy E, Malladi R, Orchard K, Pohlreich D, Tilly H, Bonifazi F, Poiré X, Guilhot F, Haenel A, Crawley C, Metzner B, Gribben J, Russell NH, Damaj G, Thomson K, Dreger P, Montoto S.

Bone Marrow Transplant. 2017 Aug;52(8):1120-1125. doi: 10.1038/bmt.2017.88. Epub 2017 May 22.

PMID:
28530668
24.

The role of extracorporeal photopheresis in the management of cutaneous T-cell lymphoma, graft-versus-host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society.

Alfred A, Taylor PC, Dignan F, El-Ghariani K, Griffin J, Gennery AR, Bonney D, Das-Gupta E, Lawson S, Malladi RK, Douglas KW, Maher T, Guest J, Hartlett L, Fisher AJ, Child F, Scarisbrick JJ.

Br J Haematol. 2017 Apr;177(2):287-310. doi: 10.1111/bjh.14537. Epub 2017 Feb 21.

25.

The scapula backward tipping test: An inter-rater reliability study.

Sebastian D, Chovvath R, Malladi R.

J Bodyw Mov Ther. 2017 Jan;21(1):69-73. doi: 10.1016/j.jbmt.2016.05.003. Epub 2016 Jun 2.

PMID:
28167193
26.

Treatment pathways and resource use associated with recurrent Hodgkin lymphoma after autologous stem cell transplantation.

Radford J, McKay P, Malladi R, Johnson R, Bloor A, Percival F, Sureda A, Peggs KS.

Bone Marrow Transplant. 2017 Mar;52(3):452-454. doi: 10.1038/bmt.2016.244. Epub 2017 Jan 16. No abstract available.

27.

Donor-derived mycosis fungoides following reduced intensity haematopoietic stem cell transplantation from a matched unrelated donor.

Kinsella FA, Amel Kashipaz MR, Scarisbrick J, Malladi R.

BMJ Case Rep. 2017 Jan 10;2017. pii: bcr2016216331. doi: 10.1136/bcr-2016-216331.

28.

Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

Genadieva-Stavrik S, Boumendil A, Dreger P, Peggs K, Briones J, Corradini P, Bacigalupo A, Socié G, Bonifazi F, Finel H, Velardi A, Potter M, Bruno B, Castagna L, Malladi R, Russell N, Sureda A.

Ann Oncol. 2016 Dec;27(12):2251-2257. doi: 10.1093/annonc/mdw421. Epub 2016 Oct 24.

29.

Pharmacy Student Attitudes and Willingness to Engage in Care with People Living with HIV/AIDS.

Rickles NM, Furtek KJ, Malladi R, Ng E, Zhou M.

Am J Pharm Educ. 2016 Apr 25;80(3):45. doi: 10.5688/ajpe80345.

30.

Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party.

Robinson SP, Boumendil A, Finel H, Blaise D, Poiré X, Nicolas-Virelizier E, Or R, Malladi R, Corby A, Fornecker L, Caballero D, Pohlreich D, Nagler A, Thieblemont C, Finke J, Bachy E, Vincent L, Schroyens W, Schouten H, Dreger P.

Bone Marrow Transplant. 2016 Mar;51(3):365-71. doi: 10.1038/bmt.2015.286. Epub 2015 Nov 30.

PMID:
26618550
31.

Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial.

Craddock C, Jilani N, Siddique S, Yap C, Khan J, Nagra S, Ward J, Ferguson P, Hazlewood P, Buka R, Vyas P, Goodyear O, Tholouli E, Crawley C, Russell N, Byrne J, Malladi R, Snowden J, Dennis M.

Biol Blood Marrow Transplant. 2016 Feb;22(2):385-390. doi: 10.1016/j.bbmt.2015.09.004. Epub 2015 Sep 9.

32.

Cervical extensor endurance test: a reliability study.

Sebastian D, Chovvath R, Malladi R.

J Bodyw Mov Ther. 2015 Apr;19(2):213-6. doi: 10.1016/j.jbmt.2014.04.014. Epub 2014 Apr 18.

PMID:
25892374
33.

Impact of ABO blood group mismatch in alemtuzumab-based reduced-intensity conditioned haematopoietic SCT.

Brierley CK, Littlewood TJ, Peniket AJ, Gregg R, Ward J, Clark A, Parker A, Malladi R, Medd P.

Bone Marrow Transplant. 2015 Jul;50(7):931-8. doi: 10.1038/bmt.2015.51. Epub 2015 Apr 13.

PMID:
25867645
34.

A multicentre UK study of GVHD following DLI: rates of GVHD are high but mortality from GVHD is infrequent.

Scarisbrick JJ, Dignan FL, Tulpule S, Gupta ED, Kolade S, Shaw B, Evison F, Shah G, Tholouli E, Mufti G, Pagliuca A, Malladi R, Raj K.

Bone Marrow Transplant. 2015 Jan;50(1):62-7. doi: 10.1038/bmt.2014.227. Epub 2014 Oct 13.

PMID:
25310308
35.

Extracorporeal photopheresis for treatment of adults and children with acute GVHD: UK consensus statement and review of published literature.

Das-Gupta E, Dignan F, Shaw B, Raj K, Malladi R, Gennery A, Bonney D, Taylor P, Scarisbrick J.

Bone Marrow Transplant. 2014 Oct;49(10):1251-8. doi: 10.1038/bmt.2014.106. Epub 2014 Jun 2. Review.

PMID:
24887389
36.

The sitting active and prone passive lag test: an inter-rater reliability study.

Sebastian D, Chovvath R, Malladi R.

J Bodyw Mov Ther. 2014 Apr;18(2):204-9. doi: 10.1016/j.jbmt.2013.08.002. Epub 2013 Sep 8.

PMID:
24725787
37.

Outcomes of EAM conditioned autologous haematopoietic SCT for lymphoma. A matched pairs retrospective single-centre study analysis.

Loke J, Ward J, Mahendra P, Chaganti S, Malladi R.

Bone Marrow Transplant. 2013 Nov;48(11):1486-7. doi: 10.1038/bmt.2013.90. Epub 2013 Jun 10. No abstract available.

PMID:
23749106
38.

Post-transplant T cell chimerism predicts graft versus host disease but not disease relapse in patients undergoing an alemtuzumab based reduced intensity conditioned allogeneic transplant.

Nikolousis E, Robinson S, Nagra S, Brookes C, Kinsella F, Tauro S, Jeffries S, Griffiths M, Mahendra P, Cook M, Paneesha S, Lovell R, Kishore B, Chaganti S, Malladi R, Raghavan M, Moss P, Milligan D, Craddock C.

Leuk Res. 2013 May;37(5):561-5. doi: 10.1016/j.leukres.2013.01.010. Epub 2013 Feb 5.

PMID:
23395505
39.

Chemokine-mediated tissue recruitment of CXCR3+ CD4+ T cells plays a major role in the pathogenesis of chronic GVHD.

Croudace JE, Inman CF, Abbotts BE, Nagra S, Nunnick J, Mahendra P, Craddock C, Malladi R, Moss PA.

Blood. 2012 Nov 15;120(20):4246-55. doi: 10.1182/blood-2012-02-413260. Epub 2012 Sep 25.

PMID:
23012327
40.

Cryopreservation of allogeneic PBSC from related and unrelated donors is associated with delayed platelet engraftment but has no impact on survival.

Medd P, Nagra S, Hollyman D, Craddock C, Malladi R.

Bone Marrow Transplant. 2013 Feb;48(2):243-8. doi: 10.1038/bmt.2012.118. Epub 2012 Jun 25.

PMID:
22732701
41.

Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML).

Goodyear OC, Dennis M, Jilani NY, Loke J, Siddique S, Ryan G, Nunnick J, Khanum R, Raghavan M, Cook M, Snowden JA, Griffiths M, Russell N, Yin J, Crawley C, Cook G, Vyas P, Moss P, Malladi R, Craddock CF.

Blood. 2012 Apr 5;119(14):3361-9. doi: 10.1182/blood-2011-09-377044. Epub 2012 Jan 10.

PMID:
22234690
42.

Methotrexate dose delivery is more important than ciclosporin level in graft-versus-host disease prophylaxis following T-replete reduced-intensity sibling allogeneic stem cell transplant.

Medd P, Monk I, Danby R, Malladi R, Clifford R, Ellis A, Roberts D, Hatton C, Vyas P, Littlewood T, Peniket A.

Int J Hematol. 2011 Sep;94(3):266-278. doi: 10.1007/s12185-011-0920-x. Epub 2011 Sep 7.

PMID:
21898174
43.

Human induced pluripotent stem cells are capable of B-cell lymphopoiesis.

Carpenter L, Malladi R, Yang CT, French A, Pilkington KJ, Forsey RW, Sloane-Stanley J, Silk KM, Davies TJ, Fairchild PJ, Enver T, Watt SM.

Blood. 2011 Apr 14;117(15):4008-11. doi: 10.1182/blood-2010-08-299941. Epub 2011 Feb 22.

PMID:
21343609
44.

Paraproteinaemia after allo-SCT, association with alemtuzumab-based conditioning and CMV reactivation.

Medd P, Littlewood S, Danby R, Malladi R, Clifford R, Wareham D, Jeffery K, Ferry B, Roberts D, Peniket A, Littlewood T.

Bone Marrow Transplant. 2011 Jul;46(7):993-9. doi: 10.1038/bmt.2010.244. Epub 2010 Oct 18.

PMID:
20956951
45.

Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML.

Malladi RK, Peniket AJ, Littlewood TJ, Towlson KE, Pearce R, Yin J, Cavenagh JD, Craddock C, Orchard KH, Olavarria E, McQuaker G, Collin M, Marks DI; British Society of Blood and Marrow Transplantation.

Bone Marrow Transplant. 2009 May;43(9):709-15. doi: 10.1038/bmt.2008.375. Epub 2008 Nov 24.

PMID:
19029965
46.

A general framework for low level vision.

Sochen N, Kimmel R, Malladi R.

IEEE Trans Image Process. 1998;7(3):310-8. doi: 10.1109/83.661181.

PMID:
18276251
47.

No more transplantation in CML?

Littlewood T, Malladi R, Peniket A.

Blood. 2007 Dec 15;110(13):4618; author reply 4618-9. No abstract available.

PMID:
18056847
48.

Aortic thrombus segmentation using narrow band active contour model.

Das B, Mallya Y, Srikanth S, Malladi R.

Conf Proc IEEE Eng Med Biol Soc. 2006;1:408-11.

PMID:
17945583
49.

High-throughput analysis of multispectral images of breast cancer tissue.

Adiga U, Malladi R, Fernandez-Gonzalez R, Ortiz de Solorzano C.

IEEE Trans Image Process. 2006 Aug;15(8):2259-68.

PMID:
16900681
50.

Fast evolution of image manifolds and application to filtering and segmentation in 3D medical images.

Deschamps T, Malladi R, Ravve I.

IEEE Trans Vis Comput Graph. 2004 Sep-Oct;10(5):525-35.

PMID:
15794135

Supplemental Content

Loading ...
Support Center